Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MH002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MRM Health Reports Safety and Efficacy Data for Pouchitis in Phase 2a Study with MH002
Details : The Company’s most advanced program MH002 is in preparation for pivotal clinical development for the treatment of Acute Pouchitis.
Product Name : MH002
Product Type : Probiotic
Upfront Cash : Inapplicable
April 16, 2024
Lead Product(s) : MH002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MH002
Therapeutic Area : Immunology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MH002 is currently the most advanced rationally-designed consortium therapy, which is investigated for the treatment of mild-to-moderate Ulcerative Colitis.
Product Name : MH002
Product Type : Probiotic
Upfront Cash : Inapplicable
September 19, 2023
Lead Product(s) : MH002
Therapeutic Area : Immunology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : M008
Therapeutic Area : Endocrinology
Study Phase : Preclinical
Sponsor : IFF
Deal Size : Undisclosed
Deal Type : Collaboration
MRM Health and IFF Reach Second Milestone in the Partnered Type 2 Diabetes Program
Details : MRM Health, working in conjunction with International Flavors & Fragrances, is advancing the LBP candidate M008 for treating NAFLD/NASH. The proprietary MRM Health CORAL® technology platform and some IFF strains will be combined to develop novel therape...
Product Name : M008
Product Type : Microorganism
Upfront Cash : Undisclosed
December 12, 2022
Lead Product(s) : M008
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Sponsor : IFF
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Preclinical
Sponsor : University Hospital of Vall d’Hebron
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Work demonstrated that 9-Strain Live Bacterial Consortium rationally selected gut commensal strains able to improve portal hypertension, insulin signaling and NAFLD activity score at histopathology, prevent fibrosis development in two different in vivo d...
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Preclinical
Sponsor : University Hospital of Vall d’Hebron
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MH002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MH002 is the first, rationally designed, consortium therapy, in which key disease-driving mechanisms guide therapeutic microbial strain selection, to enter clinical development in Pouchitis.
Product Name : MH002
Product Type : Probiotic
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : MH002
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : MH002
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MH002 is the first rationally-designed consortium therapy consists of 6 well-characterized commensal strains that are optimized to form a synergistic microecosystem against mild-to-moderate ulcerative colitis.
Product Name : MH002
Product Type : Probiotic
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : MH002
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : International Flavors and Fragrances
Deal Size : $15.1 million
Deal Type : Collaboration
DuPont Nutrition & Biosciences Enters into Collaboration
Details : In collaboration, proprietary MRM Health technology platform and some selected DuPont strains will be combined to develop novel therapeutics based on live bacterial strain combinations.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
February 19, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : International Flavors and Fragrances
Deal Size : $15.1 million
Deal Type : Collaboration